GlobeNewswire Inc.··NaBiolojic's Dual-Target Cancer Drug Shows Promise Against Resistant Tumors
Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.
TEVAclinical trialsantibody-drug conjugate